Inhibition of IL-1beta improves Glycaemia in a Mouse Model for Gestational Diabetes.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
20 02 2020
20 02 2020
Historique:
received:
20
11
2019
accepted:
29
01
2020
entrez:
22
2
2020
pubmed:
23
2
2020
medline:
13
11
2020
Statut:
epublish
Résumé
Gestational diabetes mellitus (GDM) is one of the most common diseases associated with pregnancy, however, the underlying mechanisms remain unclear. Based on the well documented role of inflammation in type 2 diabetes, the aim was to investigate the role of inflammation in GDM. We established a mouse model for GDM on the basis of its two major risk factors, obesity and aging. In these GDM mice, we observed increased Interleukin-1β (IL-1β) expression in the uterus and the placenta along with elevated circulating IL-1β concentrations compared to normoglycemic pregnant mice. Treatment with an anti-IL-1β antibody improved glucose-tolerance of GDM mice without apparent deleterious effects for the fetus. Finally, IL-1β antagonism showed a tendency for reduced plasma corticosterone concentrations, possibly explaining the metabolic improvement. We conclude that IL-1β is a causal driver of impaired glucose tolerance in GDM.
Identifiants
pubmed: 32080229
doi: 10.1038/s41598-020-59701-0
pii: 10.1038/s41598-020-59701-0
pmc: PMC7033251
doi:
Substances chimiques
Hormones
0
Interleukin-1beta
0
Steroids
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3035Références
Metzger, B. E. Summary and recommendations of the Third International Workshop-Conference on Gestational Diabetes Mellitus. Diabetes 40(Suppl 2), 197–201, https://doi.org/10.2337/diab.40.2.s197 (1991).
doi: 10.2337/diab.40.2.s197
Ben-Haroush, A., Yogev, Y. & Hod, M. Epidemiology of gestational diabetes mellitus and its association with Type 2 diabetes. Diabet. Med. 21, 103–113 (2004).
doi: 10.1046/j.1464-5491.2003.00985.x
Melchior, H., Kurch-Bek, D. & Mund, M. The Prevalence of Gestational Diabetes. Dtsch. Arztebl Int. 114, 412–418, https://doi.org/10.3238/arztebl.2017.0412 (2017).
doi: 10.3238/arztebl.2017.0412
pubmed: 5499505
pmcid: 5499505
Egan, A. M. et al. Epidemiology of gestational diabetes mellitus according to IADPSG/WHO 2013 criteria among obese pregnant women in Europe. Diabetologia 60, 1913–1921, https://doi.org/10.1007/s00125-017-4353-9 (2017).
doi: 10.1007/s00125-017-4353-9
pubmed: 6448875
pmcid: 6448875
Weissgerber, T. L. & Mudd, L. M. Preeclampsia and diabetes. Curr. Diab Rep. 15, 9, https://doi.org/10.1007/s11892-015-0579-4 (2015).
doi: 10.1007/s11892-015-0579-4
Group, H. S. C. R. et al. Hyperglycemia and adverse pregnancy outcomes. N. Engl. J. Med. 358, 1991–2002, https://doi.org/10.1056/NEJMoa0707943 (2008).
doi: 10.1056/NEJMoa0707943
Hammoud, N. M. et al. Long-term BMI and growth profiles in offspring of women with gestational diabetes. Diabetologia 61, 1037–1045, https://doi.org/10.1007/s00125-018-4584-4 (2018).
doi: 10.1007/s00125-018-4584-4
pubmed: 6448978
pmcid: 6448978
Burlina, S., Dalfra, M. G. & Lapolla, A. Short- and long-term consequences for offspring exposed to maternal diabetes: a review. J Matern Fetal Neonatal Med, 1–8, https://doi.org/10.1080/14767058.2017.1387893 (2017).
Kim, C., Newton, K. M. & Knopp, R. H. Gestational diabetes and the incidence of type 2 diabetes: a systematic review. Diabetes care 25, 1862–1868, https://doi.org/10.2337/diacare.25.10.1862 (2002).
doi: 10.2337/diacare.25.10.1862
pubmed: 12351492
pmcid: 12351492
Musial, B. et al. Proximity to Delivery Alters Insulin Sensitivity and Glucose Metabolism in Pregnant Mice. Diabetes 65, 851–860, https://doi.org/10.2337/db15-1531 (2016).
doi: 10.2337/db15-1531
pubmed: 26740602
pmcid: 26740602
Catalano, P. M., Huston, L., Amini, S. B. & Kalhan, S. C. Longitudinal changes in glucose metabolism during pregnancy in obese women with normal glucose tolerance and gestational diabetes mellitus. Am. J. Obstet. Gynecol. 180, 903–916, https://doi.org/10.1016/s0002-9378(99)70662-9 (1999).
doi: 10.1016/s0002-9378(99)70662-9
pubmed: 10203659
pmcid: 10203659
Catalano, P. M. Trying to understand gestational diabetes. Diabet. Med. 31, 273–281, https://doi.org/10.1111/dme.12381 (2014).
doi: 10.1111/dme.12381
pubmed: 24341419
pmcid: 24341419
Barbour, L. A. et al. Cellular mechanisms for insulin resistance in normal pregnancy and gestational diabetes. Diabetes Care 30(Suppl 2), S112–119, https://doi.org/10.2337/dc07-s202 (2007).
doi: 10.2337/dc07-s202
pubmed: 17596458
pmcid: 17596458
Vitoratos, N. et al. Pre- and early post-partum adiponectin and interleukin-1beta levels in women with and without gestational diabetes. Hormones 7, 230–236, https://doi.org/10.14310/horm.2002.1202 (2008).
doi: 10.14310/horm.2002.1202
pubmed: 18694861
pmcid: 18694861
Christian, L. M. & Porter, K. Longitudinal changes in serum proinflammatory markers across pregnancy and postpartum: effects of maternal body mass index. Cytokine 70, 134–140, https://doi.org/10.1016/j.cyto.2014.06.018 (2014).
doi: 10.1016/j.cyto.2014.06.018
pubmed: 25082648
pmcid: 25082648
Pantham, P., Aye, I. L. & Powell, T. L. Inflammation in maternal obesity and gestational diabetes mellitus. Placenta 36, 709–715, https://doi.org/10.1016/j.placenta.2015.04.006 (2015).
doi: 10.1016/j.placenta.2015.04.006
pubmed: 25972077
pmcid: 25972077
Katra, P., Dereke, J., Nilsson, C. & Hillman, M. Plasma Levels of the Interleukin-1-Receptor Antagonist Are Lower in Women with Gestational Diabetes Mellitus and Are Particularly Associated with Postpartum Development of Type 2 Diabetes. PLoS One 11, e0155701–e0155701, https://doi.org/10.1371/journal.pone.0155701 (2016).
doi: 10.1371/journal.pone.0155701
pubmed: 27223471
pmcid: 27223471
Kramer, F. et al. Interleukin-1beta stimulates acute phase response and C-reactive protein synthesis by inducing an NFkappaB- and C/EBPbeta-dependent autocrine interleukin-6 loop. Mol. immunology 45, 2678–2689, https://doi.org/10.1016/j.molimm.2007.12.017 (2008).
doi: 10.1016/j.molimm.2007.12.017
Ledesma, E. et al. Interleukin-1 beta (IL-1beta) induces tumor necrosis factor alpha (TNF-alpha) expression on mouse myeloid multipotent cell line 32D cl3 and inhibits their proliferation. Cytokine 26, 66–72, https://doi.org/10.1016/j.cyto.2003.12.009 (2004).
doi: 10.1016/j.cyto.2003.12.009
pubmed: 15050606
pmcid: 15050606
Challier, J. C. et al. Obesity in pregnancy stimulates macrophage accumulation and inflammation in the placenta. Placenta 29, 274–281, https://doi.org/10.1016/j.placenta.2007.12.010 (2008).
doi: 10.1016/j.placenta.2007.12.010
pubmed: 18262644
pmcid: 18262644
Hara Cde, C. et al. Characterization of Natural Killer Cells and Cytokines in Maternal Placenta and Fetus of Diabetic Mothers. J. immunology Res. 2016, 7154524, https://doi.org/10.1155/2016/7154524 (2016).
doi: 10.1155/2016/7154524
Vandanmagsar, B. et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat. Med. 17, 179–188, https://doi.org/10.1038/nm.2279 (2011).
doi: 10.1038/nm.2279
pubmed: 21217695
pmcid: 3076025
Stienstra, R. et al. The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity. Cell Metab. 12, 593–605, https://doi.org/10.1016/j.cmet.2010.11.011 (2010).
doi: 10.1016/j.cmet.2010.11.011
pubmed: 21109192
pmcid: 21109192
Uysal, K. T., Wiesbrock, S. M., Marino, M. W. & Hotamisligil, G. S. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nat. 389, 610–614, https://doi.org/10.1038/39335 (1997).
doi: 10.1038/39335
Bing, C. Is interleukin-1beta a culprit in macrophage-adipocyte crosstalk in obesity? Adipocyte 4, 149–152, https://doi.org/10.4161/21623945.2014.979661 (2015).
doi: 10.4161/21623945.2014.979661
pubmed: 26167419
pmcid: 26167419
Boni-Schnetzler, M. et al. Increased interleukin (IL)-1beta messenger ribonucleic acid expression in beta -cells of individuals with type 2 diabetes and regulation of IL-1beta in human islets by glucose and autostimulation. J. Clin. Endocrinol. Metab. 93, 4065–4074, https://doi.org/10.1210/jc.2008-0396 (2008).
doi: 10.1210/jc.2008-0396
pubmed: 18664535
pmcid: 18664535
Maedler, K. et al. Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets. J. Clin. Investigation 110, 851–860, https://doi.org/10.1172/JCI15318 (2002).
doi: 10.1172/JCI15318
Westwell-Roper, C. Y. et al. IL-1 mediates amyloid-associated islet dysfunction and inflammation in human islet amyloid polypeptide transgenic mice. Diabetologia 58, 575–585, https://doi.org/10.1007/s00125-014-3447-x (2015).
doi: 10.1007/s00125-014-3447-x
pubmed: 25491100
pmcid: 25491100
Nackiewicz, D. et al. TLR2/6 and TLR4-activated macrophages contribute to islet inflammation and impair beta cell insulin gene expression via IL-1 and IL-6. Diabetologia 57, 1645–1654, https://doi.org/10.1007/s00125-014-3249-1 (2014).
doi: 10.1007/s00125-014-3249-1
pubmed: 24816367
pmcid: 24816367
Boni-Schnetzler, M. et al. Free fatty acids induce a proinflammatory response in islets via the abundantly expressed interleukin-1 receptor I. Endocrinol. 150, 5218–5229, https://doi.org/10.1210/en.2009-0543 (2009).
doi: 10.1210/en.2009-0543
Larsen, C. M. et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N. Engl. J. Med. 356, 1517–1526, https://doi.org/10.1056/NEJMoa065213 (2007).
doi: 10.1056/NEJMoa065213
Kataria, Y., Ellervik, C. & Mandrup-Poulsen, T. Treatment of type 2 diabetes by targeting interleukin-1: a meta-analysis of 2921 patients. Semin. Immunopathology 41, 413–425, https://doi.org/10.1007/s00281-019-00743-6 (2019).
doi: 10.1007/s00281-019-00743-6
Everett, B. M. et al. Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes. J. Am. Coll. Cardiol. 71, 2392–2401, https://doi.org/10.1016/j.jacc.2018.03.002 (2018).
doi: 10.1016/j.jacc.2018.03.002
Donath, M. Y., Meier, D. T. & Böni-Schnetzler, M. Inflammation in the pathophysiology and therapy of cardiometabolic disease. Endocr. Rev. https://doi.org/10.1210/er.2019-00002 (2019).
doi: 10.1210/er.2019-00002
Newbern, D. & Freemark, M. Placental hormones and the control of maternal metabolism and fetal growth. Curr. Opin. endocrinology, diabetes, Obes. 18, 409–416, https://doi.org/10.1097/MED.0b013e32834c800d (2011).
doi: 10.1097/MED.0b013e32834c800d
Ngala, R. A., Fondjo, L. A., Gmagna, P., Ghartey, F. N. & Awe, M. A. Placental peptides metabolism and maternal factors as predictors of risk of gestational diabetes in pregnant women. A case-control study. PLoS One 12, e0181613, https://doi.org/10.1371/journal.pone.0181613 (2017).
doi: 10.1371/journal.pone.0181613
pubmed: 5521813
pmcid: 5521813
Sonagra, A. D., Biradar, S. M. & Murthy, D. S. J. Normal pregnancy- a state of insulin resistance. J. Clin. Diagn. Res. 8, CC01–CC03, https://doi.org/10.7860/JCDR/2014/10068.5081 (2014).
doi: 10.7860/JCDR/2014/10068.5081
pubmed: 4290225
pmcid: 4290225
Seki, H., Zosmer, A., Elder, M. G. & Sullivan, M. H. The regulation of progesterone and hCG production from placental cells by interleukin-1beta. Biochim. Biophys. Acta 1336, 342–348 (1997).
doi: 10.1016/S0304-4165(97)00042-1
Baratta, M., Basini, G., Bussolati, S. & Tamanini, C. Effects of interleukin-1 beta fragment (163–171) on progesterone and estradiol-17 beta release by bovine granulosa cells from different size follicles. Regul. Pept. 67, 187–194 (1996).
doi: 10.1016/S0167-0115(96)00123-1
Fleshner, M. et al. Interleukin-1 beta induced corticosterone elevation and hypothalamic NE depletion is vagally mediated. Brain Res. Bull. 37, 605–610, https://doi.org/10.1016/0361-9230(95)00051-f (1995).
doi: 10.1016/0361-9230(95)00051-f
pubmed: 7670884
pmcid: 7670884
Andreis, P. G. et al. Interleukin-1 beta enhances corticosterone secretion by acting directly on the rat adrenal gland. Endocrinol. 129, 53–57, https://doi.org/10.1210/endo-129-1-53 (1991).
doi: 10.1210/endo-129-1-53
van der Meer, M. J. et al. Acute stimulation of the hypothalamic-pituitary-adrenal axis by IL-1 beta, TNF alpha and IL-6: a dose response study. J. Endocrinol. Invest. 19, 175–182 (1996).
doi: 10.1007/BF03349862
pubmed: 8743284
pmcid: 8743284
Beach, J. E. et al. Rapid release of multiple hormones from rat pituitaries perifused with recombinant interleukin-1. Life Sci. 44, 1–7, https://doi.org/10.1016/0024-3205(89)90211-7 (1989).
doi: 10.1016/0024-3205(89)90211-7
pubmed: 2536450
pmcid: 2536450
Johnson, J. D., O’Connor, K. A., Watkins, L. R. & Maier, S. F. The role of IL-1β in stress-induced sensitization of proinflammatory cytokine and corticosterone responses. Neurosci. 127, 569–577, https://doi.org/10.1016/j.neuroscience.2004.05.046 (2004).
doi: 10.1016/j.neuroscience.2004.05.046
Schmidt, E. M. et al. Effects of an interleukin-1 receptor antagonist on human sleep, sleep-associated memory consolidation, and blood monocytes. Brain, behavior, Immun. 47, 178–185, https://doi.org/10.1016/j.bbi.2014.11.012 (2015).
doi: 10.1016/j.bbi.2014.11.012
Urwyler, S. A., Schuetz, P., Ebrahimi, F., Donath, M. Y. & Christ-Crain, M. Interleukin-1 Antagonism Decreases Cortisol Levels in Obese Individuals. J. Clin. Endocrinol. Metab. 102, 1712–1718, https://doi.org/10.1210/jc.2016-3931 (2017).
doi: 10.1210/jc.2016-3931
pubmed: 28324042
pmcid: 28324042
van Asseldonk, E. J. et al. One week treatment with the IL-1 receptor antagonist anakinra leads to a sustained improvement in insulin sensitivity in insulin resistant patients with type 1 diabetes mellitus. Clin. immunology 160, 155–162, https://doi.org/10.1016/j.clim.2015.06.003 (2015).
doi: 10.1016/j.clim.2015.06.003
Dror, E. et al. Postprandial macrophage-derived IL-1[beta] stimulates insulin, and both synergistically promote glucose disposal and inflammation. Nat Immunol 18, 283–292, https://doi.org/10.1038/ni.3659 , http://www.nature.com/ni/journal/v18/n3/abs/ni.3659.html#supplementary-information (2017).
Nordmann, T. M. et al. The Role of Inflammation in β-cell Dedifferentiation. Sci. Rep. 7, 6285–6285, https://doi.org/10.1038/s41598-017-06731-w (2017).
doi: 10.1038/s41598-017-06731-w
pubmed: 28740254
pmcid: 28740254
Strajhar, P. et al. Acute Effects of Lysergic Acid Diethylamide on Circulating Steroid Levels in Healthy Subjects. J. Neuroendocrinol. 28, 12374, https://doi.org/10.1111/jne.12374 (2016).
doi: 10.1111/jne.12374
pubmed: 26849997
pmcid: 26849997
Smith, C. J. F. & Chambers, C. FRI0107 Five successful pregnancies with antenatal anakinra exposure. Ann. Rheumatic Dis. 77, 598–598, https://doi.org/10.1136/annrheumdis-2018-eular.1849 (2018).
doi: 10.1136/annrheumdis-2018-eular.1849
Youngstein, T. et al. International multi-centre study of pregnancy outcomes with interleukin-1 inhibitors. Rheumatol. 56, 2102–2108, https://doi.org/10.1093/rheumatology/kex305 (2017).
doi: 10.1093/rheumatology/kex305
Yockey, L. J. & Iwasaki, A. Interferons and Proinflammatory Cytokines in Pregnancy and Fetal Development. Immun. 49, 397–412, https://doi.org/10.1016/j.immuni.2018.07.017 (2018).
doi: 10.1016/j.immuni.2018.07.017
Andersen, C. J., Murphy, K. E. & Fernandez, M. L. Impact of Obesity and Metabolic Syndrome on Immunity. Adv. Nutr. 7, 66–75, https://doi.org/10.3945/an.115.010207 (2016).
doi: 10.3945/an.115.010207
pubmed: 26773015
pmcid: 26773015